TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7316527
Drug: Once-daily ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily ultraviolet radiation treatment with coal tar
Study: 7316527
Drug: Twice-daily ultraviolet
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily ultraviolet radiation treatment with coal tar
Study: 31006575
Drug: Annual school-based
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual school-based treatment with albendazole
Study: 31006575
Drug: Annual community-wide
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual community-wide treatment with albendazole
Study: 31006575
Drug: Biannual community-wide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual community-wide treatment with albendazole
Study: 27810407
Drug: Ultrasound-guided continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided continuous PV catheter with a continuous infusion of 0.2% ropivacaine
Study: 25828982
Drug: Aftercare services
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aftercare services (treatment follow-up, family psychoeducation, patient social skills training)
Study: 21930734
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy (target dose 20 mg/week)
Study: 19923530
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (0, 5, 10, or 15 mg)
Study: 17322146
Drug: FBT 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBT 800 microg (oral)
Study: 24559814
Drug: Topical Trikatu
Normalized name: ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical Trikatu preparation
Study: 23061989
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + metformin
Study: 19728035
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen patch 0.1 mg
Study: 19728035
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/day to 100 mg/day for 9 weeks
Study: 17664519
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (cognitive-behavioral therapy and pharmacological management)
Study: 10914616
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone extract (50 mg genistin and daidzin per day)
Study: 9180289
Drug: low-dose Ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose Ara-C with growth factors
Study: 9180289
Drug: low-dose Ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose Ara-C without growth factors
Study: 31630990
Drug: Adjuvanted inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted inactivated vaccine
Study: 31630990
Drug: Intramuscular study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular study product or placebo
Study: 31630990
Drug: Intranasal study
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal study product or placebo
Study: 27009046
Drug: Morita Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morita Therapy plus treatment as usual
Study: 24311443
Drug: HT (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT (conjugated estrogens, 0.625 mg/d)
Study: 19950737
Drug: Diclofenac patch
Normalized name: diclofenac Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac patch (180 mg of diclofenac epolamine salt)
Study: 11566277
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 160 mg/g methyl 5-aminolevulinate for 3 hours
Study: 11566277
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 16 mg/g methyl 5-aminolevulinate for 3 or 18 hours
Study: 11566277
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 80 mg/g methyl 5-aminolevulinate for 3 or 18 hours
Study: 9591168
Drug: Multimodal pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pain treatment program
Study: 9591168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (fibromyalgia patients who failed to qualify for the treatment program)
Study: 28926514
Drug: 0.003% estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.003% estradiol vaginal cream (15 μg estradiol; 0.5 g cream) applied daily for 2 weeks followed by three applications/week for 10 weeks
Study: 28926514
Drug: 0.003% estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.003% estradiol vaginal cream
Study: 28926514
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 g cream)
Study: 27286071
Drug: Work-focused cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-focused cognitive-behavioural therapy plus convergence dialogue meeting (CDM)
Study: 27286071
Drug: Work-focused cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-focused cognitive-behavioural therapy without CDM
Study: 23881566
Drug: Umeclidinium (100-1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium (100-1,000 μg)
Study: 23881566
Drug: Umeclidinium (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium (500 μg)
Study: 23881566
Drug: Umeclidinium (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium (1,000 μg)
Study: 12154110
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro sodium concentrations (154 to 308 mmol/L)
Study: 8560359
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nitrofurantoin macro-crystals 3 times daily for 7 days (Group A)
Study: 8560359
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nitrofurantoin macro-crystals 4 times daily for 7 days (Group B)
Study: 2127940
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (1 gram of cefotetan)
Study: 28371941
Drug: Mirogabalin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin (all doses)
Study: 19272597
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL water intake
Study: 19272597
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL water intake
Study: 19272597
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL water intake
Study: 15328306
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg) administered 5 hours before exercise trial
Study: 15328306
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 5 hours before exercise trial
Study: 11887898
Drug: Xi's capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xi's capsule
Study: 9557471
Drug: Pefloxacin 800
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 800 mg i.v. slow infusion
Study: 9557471
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g i.v.
Study: 3524439
Drug: 6.5% tioconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5% tioconazole ointment
Study: 3524439
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clotrimazole vaginal tablets (3-day course)
Study: 30067077
Drug: 30s eccentric,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30s eccentric, 30s concentric, and 30s eccentric (e.g., 1.5 repetitions; n = 21)
Study: 25935645
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with topotecan and cisplatin
Study: 25935645
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with consolidation chemotherapy (CCRT + CT)
Study: 21640258
Drug: VEGF Trap-Eye
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap-Eye 2 mg every 4 weeks during the fixed-dosing phase
Study: 21640258
Drug: VEGF Trap-Eye
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap-Eye (after 12-week fixed-dosing phase)
Study: 17034605
Drug: Intensive pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive pelvic floor muscle therapy (PFMT)
Study: 15165091
Drug: Talc (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talc (5 g)
Study: 15165091
Drug: Quinacrine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinacrine (500 mg)
Study: 11261275
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy (HDCT) with autologous stem cell transplantation
Study: 17095559
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg every 4 weeks)
Study: 4028987
Drug: Four 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 0.1 mg doses of fenoterol each at 30 minute intervals
Study: 4028987
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.4 mg fenoterol aerosol
Study: 27660163
Drug: Bimonthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimonthly intravitreal injections of ranibizumab (IVR)
Study: 26312955
Drug: Codeine/acetaminophen for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/acetaminophen for 10 days post‐tonsillectomy (5 days scheduled, followed by 5 days as‐needed)
Study: 12921245
Drug: Meropenem 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 0.5 g every 8 hours as a 3-hour infusion
Study: 12921245
Drug: Meropenem 2
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2 g every 8 hours as a 3-hour infusion
Study: 10866910
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + GBP (600 mg)
Study: 10866910
Drug: Morphine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (60 mg) + GBP (600 mg)
Study: 10866910
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + placebo
Study: 10866910
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + GBP
Study: 9378841
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of caffeine
Study: 7505434
Drug: gammaglobulin 150
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gammaglobulin 150 mg/kg x 2 on the first day of admission
Study: 7505434
Drug: gammaglobulin 300
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gammaglobulin 300 mg/kg/die for 3 days
Study: 7505434
Drug: gammaglobulin 150
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gammaglobulin 150 mg/kg/die during hospitalization
Study: 3885107
Drug: Ceftizoxime 2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime 2-g dose at cord clamping
Study: 25732625
Drug: Beloranib 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beloranib 0.6 mg
Study: 25732625
Drug: Beloranib 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beloranib 1.2 mg
Study: 25732625
Drug: Beloranib 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beloranib 2.4 mg
Study: 23088807
Drug: EVLA810-1 (810-nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVLA810-1 (810-nm axial diode laser with 4-F introducer, 0.018" guidewire, 22-G needle)
Study: 22106845
Drug: Group relaxation
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group relaxation training sessions according to the Yoga in Daily Life(®) system, plus audiocassette recordings for 3 weeks at home.
Study: 19142129
Drug: Anterior chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior chamber reformation with balanced salt solution and concurrent drainage of choroidal effusion
Study: 19142129
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy with atropine, phenylephrine, and in select cases oral acetazolamide
Study: 18181342
Drug: Cisplatin at
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at 80 mg/m2 and irinotecan at 200 mg/m2 on day 1, followed by docetaxel at 75 mg/m2 on day 22, in 6-week cycles for a maximum of 3 cycles.
Study: 8542099
Drug: Intensive subcutaneous
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive subcutaneous insulin therapy (ISIT) alone
Study: 205687
Drug: Control plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control plasma (lacking varicella-zoster virus antibodies)
Study: 28601733
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 1.2% simvastatin gel
Study: 26493253
Drug: Passeo-18 Lux
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passeo-18 Lux DEB (paclitaxel-coated drug-eluting balloon)
Study: 15086488
Drug: High producer
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High producer genotypes for IL-6 (G/G and G/C) and TNF-alpha (G/A and A/A)
Study: 15086488
Drug: High and
Normalized name: Ascensia Autodisc High and Low Control Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: High and intermediate producer genotypes for IL-10 (G/G and G/A)
Study: 15086488
Drug: TNF-alpha high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha high producer genotype (G/A and A/A)
Study: 15086488
Drug: TNF-alpha high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha high producer and IL-10 low producer genotype combination
Study: 11747684
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/day or 10 mg/day)
Study: 11747684
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 or 120 mg/day)
Study: 11747684
Drug: Combination hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination hormone replacement therapy (HRT)
Study: 11747684
Drug: Alendronate, Raloxifene,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, Raloxifene, or Combination HRT
Study: 7826249
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 mg single dose) before amiodarone therapy
Study: 7826249
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 mg single dose) after one month of amiodarone therapy (400 mg daily)
Study: 7826249
Drug: Amiodarone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (400 mg daily for one month)
Study: 29574365
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (days 0, 14, 28, then every 28 days)
Study: 29574365
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg (daily)
Study: 26307942
Drug: Computer-assisted behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted behavioral treatment for CUD with tobacco intervention and nicotine-replacement therapy (NRT)
Study: 26307942
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (treatment for CUD but not tobacco)
Study: 10695692
Drug: Alendronate sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate sodium, 5 mg/d (increased to 10 mg/d after 2 years)
Study: 786310
Drug: Piracetam therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam therapy at a dosage of 3 X 1600 mg per day
Study: 786310
Drug: Piracetam therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam therapy at a dosage of 3 X 800 mg per day
Study: 25220709
Drug: LNG/EE contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE contraceptive patch
Study: 25220709
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral contraceptive 20 (LNG 100 μg per EE 20 μg)
Study: 25220709
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral contraceptive 30 (LNG 150 μg per EE 30 μg)
Study: 20934757
Drug: 8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/day oral essential amino acids (EAAs)
Study: 15504997
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg exenatide twice daily
Study: 15504997
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg exenatide twice daily
Study: 8950733
Drug: Amniotic fluid
Normalized name: Human Amniotic Fluid
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotic fluid insulin concentration (AFI) based treatment
Study: 8950733
Drug: Mean maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mean maternal blood glucose values (MBG) based treatment
Study: 7138234
Drug: Clonidine hydrochloride
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine hydrochloride and naltrexone hydrochloride combination treatment
Study: 31584030
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish with prior oral prophylaxis
Study: 31584030
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish without prior oral prophylaxis
Study: 28656910
Drug: levocetirizine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: levocetirizine 10 mg
Study: 28656910
Drug: levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: levocetirizine 5 mg + montelukast 10 mg
Study: 31381231
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (MTX)
Study: 19588534
Drug: 595 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595 nm pulsed dye laser (PDL) treatment, 4 treatments at 2-week intervals, 15 J/cm2 energy, 3 ms pulse length, no cooling, 7 mm spot size with 10% overlap
Study: 19588534
Drug: 595 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595 nm pulsed dye laser (PDL) treatment
Study: 17521782
Drug: Trivalent A/C/W135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent A/C/W135 polysaccharide vaccine
Study: 17521782
Drug: Tetravalent A/C/Y/W135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent A/C/Y/W135 polysaccharide vaccine
Study: 2636654
Drug: Ketoacid mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoacid mixture (KAM) containing 10.9% (R,S) alpha-keto-beta-methylvalerate, meal dose of 6.2 +/- 0.25 g or 9.3 +/- 0.55 g
Study: 606773
Drug: A/Shope vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/Shope vaccine (200 CCA units/dose)
Study: 606773
Drug: A/X-53 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/X-53 vaccine (200 CCA units/dose)
Study: 23370663
Drug: 100 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg/kg A(1-7)
Study: 23370663
Drug: 300 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mcg/kg A(1-7)
Study: 19437312
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg single dose of azithromycin
Study: 19437312
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg single dose of azithromycin
Study: 11380220
Drug: Oral paste
Normalized name: Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paste containing antibiotics polymyxin E, tobramycin, and amphotericin B (PTA group)
Study: 15144469
Drug: Symptomatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic drugs only (Control)
Study: 29504780
Drug: Reduced nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced nicotine content (RNC) cigarettes (0.4 mg/g to 15.8 mg/g nicotine)
Study: 29504780
Drug: Reduced nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced nicotine content (RNC) cigarettes (0.4 mg/g)
Study: 27475338
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin B6 (60 mg of intravenous pyridoxal 5'-phosphate after each thrice-weekly hemodialysis session)
Study: 15370183
Drug: Individualized homeopathy
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathy treatment
Study: 15370183
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (continued)
Study: 15370183
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (switched to placebo)
Study: 8087784
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of chemotherapy
Study: 3195529
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus 5 mL/kg/d for four days of IgM-enriched immunoglobulin intravenously